In Vitro Susceptibility of Burkholderia cepacia Complex Isolated from Cystic Fibrosis Patients to Ceftazidime-Avibactam and Ceftolozane-Tazobactam | Zendy

Annelien Van Dalem | Zendy; Margaux Herpol | Zendy; Fedoua Echahidi | Zendy; Charlotte Peeters | Zendy; Ingrid Wybo | Zendy; Elke De Wachter | Zendy; Peter Vandamme | Zendy; Denis Piérard | Zendy

Open Access

In Vitro Susceptibility of Burkholderia cepacia Complex Isolated from Cystic Fibrosis Patients to Ceftazidime-Avibactam and Ceftolozane-Tazobactam

Author(s) -

Annelien Van Dalem,

Margaux Herpol,

Fedoua Echahidi,

Charlotte Peeters,

Ingrid Wybo,

Elke De Wachter,

Peter Vandamme,

Denis Piérard

Publication year - 2018

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00590-18

Subject(s) - ceftazidime/avibactam , burkholderia cepacia complex , cystic fibrosis , burkholderia , microbiology and biotechnology , ceftazidime , avibactam , antibiotics , trimethoprim , medicine , in vitro , sulfamethoxazole , biology , pseudomonas aeruginosa , bacteria , genetics , biochemistry

We tested thein vitro susceptibility of ceftazidime-avibactam and ceftolozane-tazobactam and 13 other antibiotics against 91Burkholderia cepacia complex (BCC) strains isolated from cystic fibrosis patients since 2012. The highest susceptibility (82%) was found for trimethoprim-sulfamethoxazole.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog